- Home
- NGNE vs ATLN Comparison
NGNE vs ATLN Comparison
Compare NGNE & ATLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- ATLN
- Stock Information
- Founded
- NGNE 2003
- ATLN 2014
- Country
- NGNE United States
- ATLN United States
- Employees
- NGNE N/A
- ATLN N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- ATLN
- Sector
- NGNE Health Care
- ATLN
- Exchange
- NGNE Nasdaq
- ATLN NYSE
- Market Cap
- NGNE 230.0M
- ATLN 186.7M
- IPO Year
- NGNE N/A
- ATLN 2021
- Fundamental
- Price
- NGNE $17.36
- ATLN $2.50
- Analyst Decision
- NGNE Strong Buy
- ATLN
- Analyst Count
- NGNE 6
- ATLN 0
- Target Price
- NGNE $60.80
- ATLN N/A
- AVG Volume (30 Days)
- NGNE 277.9K
- ATLN 20.3K
- Earning Date
- NGNE 11-18-2024
- ATLN 01-01-0001
- Dividend Yield
- NGNE N/A
- ATLN N/A
- EPS Growth
- NGNE N/A
- ATLN N/A
- EPS
- NGNE N/A
- ATLN N/A
- Revenue
- NGNE $925,000.00
- ATLN $429,260,149.00
- Revenue This Year
- NGNE N/A
- ATLN N/A
- Revenue Next Year
- NGNE N/A
- ATLN N/A
- P/E Ratio
- NGNE N/A
- ATLN N/A
- Revenue Growth
- NGNE N/A
- ATLN 5.50
- 52 Week Low
- NGNE $14.42
- ATLN $1.30
- 52 Week High
- NGNE $74.49
- ATLN $8.98
- Technical
- Relative Strength Index (RSI)
- NGNE 44.25
- ATLN N/A
- Support Level
- NGNE $16.72
- ATLN N/A
- Resistance Level
- NGNE $19.97
- ATLN N/A
- Average True Range (ATR)
- NGNE 2.39
- ATLN 0.00
- MACD
- NGNE 0.08
- ATLN 0.00
- Stochastic Oscillator
- NGNE 19.43
- ATLN 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
About ATLN ATLANTIC INTERNATIONAL CORP
Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.